Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Coherus Oncology (CHRS) Other Gross PP&E Adjustments (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Other Gross PP&E Adjustments for 13 consecutive years, with -$21.0 million as the latest value for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 179.17% to -$21.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$21.0 million through Dec 2025, down 179.17% year-over-year, with the annual reading at -$21.0 million for FY2025, 179.17% down from the prior year.
  • Other Gross PP&E Adjustments hit -$21.0 million in Q4 2025 for Coherus Oncology, down from -$7.5 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $28.9 million in Q3 2022 to a low of -$21.0 million in Q4 2025.
  • Historically, Other Gross PP&E Adjustments has averaged $14.5 million across 5 years, with a median of $24.8 million in 2024.
  • Biggest YoY gain for Other Gross PP&E Adjustments was 71.66% in 2021; the steepest drop was 1004.7% in 2021.
  • Year by year, Other Gross PP&E Adjustments stood at -$14.1 million in 2021, then skyrocketed by 33.74% to -$9.3 million in 2022, then dropped by 12.55% to -$10.5 million in 2023, then increased by 28.59% to -$7.5 million in 2024, then crashed by 179.17% to -$21.0 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for CHRS at -$21.0 million in Q4 2025, -$7.5 million in Q4 2024, and $23.5 million in Q3 2024.